🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

My thanks to #IMMUNOmodel COSTAction for the opportunity to speak at the 3rd Annual Meeting in Warsaw, Poland on the challenges facing pre-clinical researchers working on modelling immunotherapies! DCU Research DCU Science and Health DCU Life Sciences Institute DCU School of Biotechnology immunomodel

Honoured to be asked to serve another term on Breast Cancer Scientific Committee @TRIOncology. Under Dr Slamon’s leadership, TRIO has done some of the most important scientifically based studies in breast cancer. TRIO would be great for YOUR next trial.

We at Dublin City University Cancer Research Labs had a great AACR last month. Great work by Denis Collins, Debbie O Reilly, Myra Castel, Marta Valenti, Arnau Cuy-Saques led to multiple posters. I also presented updated data on Fianlimab/Cemiplimab in Melanoma.

Also presented NATALEE update at ESMO breast.

With ⁦Denis Collins⁩ at his poster AACR last month.

With brilliant young breast cancer researcher Debbie O’Reilly at her poster. ⁦Dublin City University⁩

From AACR last month

A real honour to speak Peter Mac Cancer Centre My old pal and fellow Prof Pru Francis now a world-recognised breast cancer researcher.

One of my biggest thrills of the last year was being invited to speak ⁦Dartmouth Cancer Center⁩ hosted by ⁦Linda Vahdat⁩ . A former brilliant fellow of mine, chief of oncology at Dartmouth.

Out now & open access in Nature Medicine concurrent with presentation at #ASCO2025 is NeoCOAST-2! I have been delighted to collaborate on the first platform neoadjuvant trial in lung cancer led by Dr. Tina Cascone nature.com/articles/s4159… ! #LCSM 1/6

In this platform phase 2 trial pts were enrolled to neoadjuvant combinations of platinum doublet chemo plus durvalumab & either oleclumab (anti-CD73) or monalizumab (anti-NKG2A) or to carbo-DatoDXD-Durva (the neoadjuvant ADC study. Rates of surgery were high. 2/6

pCR rates were compared to the external reference of the Aegean phase 3 trial of chemo-Durva (~17% pCR). In NC-2 the dato-dxd combination delivered the highest pCR rate - an impressive 35%! 3/6

Interestingly pCR rates were relatively similar in both PD-L1 positive and negative tumors in the Dato-dxd arm 4/6

Perhaps because of the early disease stage and short course of dato-did therapy (4 neoadjuvant cycles only) toxicity rates were relatively low in the ADC combo arm compared to tox seen in advanced disease studies 5/6

What have we learned? As the first platform neoadjuvant phase 2 trial post adoption of neoadjuvant therapy in lung cancer NC-2 provides a template for rational drug development in resectable lung cancer. pCR is a promising endpoint and dato-DXD shows particular activity 6/6

Dr Sarah Lochrin on the #ASCO25 #ASCO 2025 podium where she delivered a great talk on single cycle neo-adjuvant ipilimumab +nivolumab in melanoma. Dr Lochrin will be joining us as consultant oncologist in SVH later this year.

Doctors find ourselves in a difficult position. We have great accountability, combined with little authority.

Tebebtafusp is the 1st drug to show overall survival advantage in metastatic uveal (eye) melanoma. We gave the first dose outside of compassionate access last week. Laya Healthcare 👍! Sadly-now the latest example of 2Tier care. Not available in HSE.

Great to see TCHL study published in Acta Oncologoca. Big thank you to Alex J Eustace for all his work. This study derived from original lab work in DCU. We shouldn’t forget the TKIs doi: 10.2340/1651-226X.2025.43143. PMID: 4046899

Our translational cancer research Dublin City University has been led to multiple clinical trials.